Incidence and survival of stomach cancer in a high-risk population of Chile

Abstract

AIM:To study the incidence and survival rate of stomach cancer (SC) and its associated factors in a high risk population in Chile. METHODS:The population-based cancer registry of Valdivia, included in the International Agency for Research on Cancer system, covers 356 396 residents of Valdivia Province, Southern Chile. We studied all SC cases entered in this Registry during 1998Registry during -2002. Population data came from the Chilean census (2002). Standardized incidence rates per 100 000 inhabitants (SIR) using the world population, cumulative risk of developing cancer before age 75, and rate ratios by sex, age, ethnicity and social factors were estimated. Relative survival (Ederer Ⅱ method) and age-standardized estimates (Brenner method) were calculated. Specific survival rates (Kaplan-Meier) were measured at 3 and 5 years and survival curves were analyzed with the Logrank and Breslow tests. Survival was studied in relation to demographics, clinical presentation, laboratory results and medical management of the cases. Those variables significantly associated with survival were later included in a Cox multivariate model. RESULTS:Between 1998 and 2002, 529 primary gastric cancers occurred in Valdivia (crude incidence rate 29.2 per 100 000 inhabitants). Most cases were male (69.0%), residents of urban areas (57.5%) and Hispanic (83.2%), with a low education level (84.5% < 8 school years). SC SIR was higher in men than women (40.8 and 14.8 respectively, P < 0.001), risk factors were low education RR 4.4 (95% CI: 2.9-6.8) and 1.6, (95% CI: 1.1-2.1) for women and men respectively and Mapuche ethnicity only significant for women (RR 2.2, 95% CI: 1.2-3.7). Of all cases, 76.4% were histologically confirmed, 11.5% had a death certificate only (DCO), 56.1% were TNM stage Ⅳ; 445 cases (84.1%) were eligible for survival analysis, all completed five years follow-up; 42 remained alive, 392 died of SC and 11 died from other causes. Specific 5-year survival, excluding cases with DCO, was 10.6% (95% CI: 7.7-13.5); 5-year relative survival rate was 12.3% (95% CI: 9.1-16.1), men 10.9% (95% CI: 7.4-15.2) and women 16.1% (95% CI: 9.5-24.5). Fiveyear specific survival was higher for patients aged < 55 years (17.3%), with intestinal type of cancer (14.6%), without metastasis (22.2%), tumor size < 4 cm (60.0%), without lymphatic invasion (77.1%), only involvement of the mucous membrane (100%). Statistically significant independent prognostic factors were: TNM staging, diffuse type, metastasis, supraclavicular adenopathy, palpable tumor, and hepatitis or ascites. CONCLUSION:Social determinants are the main risk factors for SC, but not for survival. An advanced clinical stage at consultation is the main cause of poor SC survival.

MicroRNA-144 functions as a tumor suppressor in gastric cancer by targeting cyclooxygenase-2

“…Gastric cancer (GC), one of the leading causes of cancer-associated mortality, is a malignant epithelial cancer that poses a serious threat to public health, particularly in China (1,2). Current treatments for GC depend on the tumor-node-metastasis stage, the type of cancer tissue (intestinal or diffuse) and the patient's physical condition (3,4).…”

Gastrectomía extendida en cáncer gástrico: Evaluación de la morbilidad y mortalidad postoperatoria

“…Fax: 56-2-4218597 E-mail: delafueh@yahoo.com E l cáncer gástrico tiene una alta incidencia en el mundo y es la segunda causa de muerte por neoplasia maligna 1 . lamentablemente, a pesar de los avances importantes en el diagnós-tico y tratamiento, la sobrevida a 5 años es pobre, porque está determinada fundamentalmente por el diagnóstico tardío que tienen la mayoría de los enfermos 2 . En chile, es la primera causa de muerte por cáncer, el número de fallecidos es cercana a la mortalidad observada en enfermedades crónicas prevalentes 3 , más de 80% de los pacientes se presentan en etapas avanzadas y 50% de ellos tienen compromiso de órganos vecinos 4 .…”

Increased Expression of P2RY2, CD248 and EphB1 in Gastric Cancers from Chilean Patients

“…While in most countries the mortality rate is declining, in Chile the mortality rate has remained relatively stable in the last 3 decades (Arancibia et al, 2009). Furthermore, GC currently ranks as the leading cause of cancer death in Chile, with a crude mortality rate of 20/100.000 inhabitants over the last 10 years (25.1/100,000 males and 13.2/100,000 females) (Heise et al, 2009). In 2002, 3,115 deaths were secondary to GC in Chile (Arancibia et al, 2009).…”